A A A
-->

NET-Studien

  AXI-IIG-02

a phase II / III randomized double-blind study of Sandostatin LAR in combination with Axitinib versus Sandostatin LAR with placebo in patients with advanced G1-G2 neuroendocrinec tumours (WHO2010) of non pancreatic

Ansprechpartner:

Prüfer: Dr. Grote

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

  CPDR001E2201

an open label phase II study to evaluate the efficacy and safety of PDR 001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin who have progressed on prior traetment

Ansprechpartner:

Prüfer:  Dr. A Rinke

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

  Compete

A prospective, randomised, controlled, open label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatinreceptor positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET)

Ansprechpartner:

Prüfer:  Dr. A. Rinke

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

  Avenec

A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab in Patients With Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive After First Line Chemotherapy

Ansprechpartner:

Prüfer:  Dr. A. Rinke

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

  RamuNET

 A multicenter single-arm pilot study of ramucirumab in combina-tion with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors

Ansprechpartner:

Prüfer: Prof. Gress

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

  Sonnet

Ansprechpartner:

Prüfer:  Dr. A. Rinke

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

  Seqtor

Randomized phase III openn label cross over study to compare the efficacy and safety of everolimus followed by chemotherapy witz STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNET's

Ansprechpartner:

Prüfer:  Dr. A. Rinke

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

 

  Evinec

Zweitlinientherapie bei schlecht differenzierten neuroendokrinen Karzinom/neuroendokrines Karzinom G3 (WHO2010) und neuroendokrinem Tumor G3 - eine "Investigator initiated" Phase II Studie 

Ansprechpartner:

Prüfer:  Dr. A. Rinke

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose

 

  Lebensqualität NET (Patienten unter verschiedenen Therapien)

Ansprechpartner:

Prüfer: 

Studiensekretariat: D. Stark, E. Kort, F. Trebes-Börner, A. Brose